Equity
€304,221 ▲ 88.8%
Equity rose in 2025 from €161,107 to €304,221.
TM4
Lifetime
6 annual accounts with figures on one time axispeak €301,244 (2023)
€234,394▲ 0.5%
peak €212,891 (2023)
€143,114▼ 8.3%
peak €304,221 (2025)
€304,221▲ 88.8%
€17,891▼ 73.2%
Board1 name since 2019
1 director
Documentsfilings and deeds
07-07-202624 days before the deadline
2025micro format
Equity from €161,107 to €304,221Debts from €66,652 to €17,891
Key points
from the 2025 annual accountsTurnover
≈ €440,000 estimated
The micro format states no turnover.
Liquidity
17.15 was 3.33 in 2024
Short-term debts fell from €50,700 to €16,658.
Filings
6 annual accounts 3 late
The 2020 accounts came latest: 111 days after the end of the period.
Starting capital
€5,000 100 shares
Position in the sector
94.4%
Higher solvency than 90% of companies in human health. Sector median 63.0% · 21,311 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 26,969 companies had the same profile as TM4 has now. Each dot stands for 68 companies, two years later.
94.9%
were still trading
3.4%
stopped another way
1.6%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 26,969 companies, not a prediction for TM4. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0740463950
Incorporation
Founding capital of €5,000, 100 shares · Founder: · Appointment: (director) · published on 30-12-2019 · Gazette deed
First establishment
Oude Geraardsbergsestraat 27B, Lennik
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| TM4 Lennik | €322,112 | €234,394 | 94.4% | - |
| DEMANapath Rotselaar | €373,351 | €227,475 | 48.3% | - |
| PHILIPPE LEUNE Roosdaal | €304,623 | €212,725 | 51.0% | - |
| CABINET MEDICAL DES DOCTEURS LOMBARD-ERPICUM Esneux | €313,530 | €235,243 | 5.9% | - |
| Dr. Wout De Ruyck Psychiatrie Nazareth-De Pinte | €316,897 | €228,856 | 4.7% | - |
| Dr. Marlies De Bock, Oncologie Gavere | €303,112 | €234,518 | 20.8% | - |
| Dr. Bekkhan Mamaev, anesthesie Lanaken | €331,150 | €242,613 | 89.0% | - |
These companies have the same main activity as TM4: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €303,000 and €373,000, founded between 2019 and 2020.
Official details
Source: KBO- Status
- Active since 24-12-2019Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.298.298.2041750 Lennik, since 24-12-2019
- Financial year end
- 31 December
- Peppol
- Reachable since 24-11-2023
Annual accounts 2025
- €322,112▲ 41.4%
- Filing
- Filed on 07-07-2026, 24 days before the end of the filing period
Insights on TM4
TM4 files the micro format. That format states no turnover. The gross margin rose from €56,962 in 2020 to €234,394 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about TM4
- What is the company number of TM4?
- The company number of TM4 is 0740.463.950. The VAT number is the same number with BE in front: BE 0740.463.950.
- Where is TM4 based?
- The registered office is at Oude Geraardsbergsestraat 27B, 1750 Lennik.Company details
- What does TM4 do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of TM4?
- TM4 is a private limited company (BV).
- When was TM4 founded?
- TM4 was founded on 24-12-2019.
- Is TM4 still active?
- Yes, TM4 is an active enterprise in the KBO register.
- What is the turnover of TM4?
- The turnover in financial year 2025 is ≈ €440,000. This figure is estimated from the gross margin of €234,394 and 41 comparable companies (NACE 86220). It probably lies between €370,000 and €580,000.Financials
- Is TM4 profitable?
- In financial year 2025, TM4 made a profit of €143,114.
- Where can I find the annual accounts of TM4?
- TM4 filed 6 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of TM4 due?
- TM4 must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.